Vivani Medical, Inc. (VANI) - 10-K Summary
Business Context and Reporting Period
Company: Vivani Medical, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Vivani is a clinical-stage biopharmaceutical company developing miniaturized, subdermal drug implants using its proprietary NanoPortal technology. The technology aims to provide ultra long-acting, near constant-rate delivery of medicines to treat chronic diseases, specifically addressing medication non-adherence. The company operates two segments: the Biopharm Division (primary focus) and the Neurostimulation Division (Cortigent, Inc., a wholly-owned subsidiary).
Key Pipeline Assets:
- NPM-115: High-dose exenatide implant for chronic weight management. First-in-human clinical trial (LIBERATE-1) initiated in Australia in late 2024; full enrollment achieved in March 2025. Top-line data expected mid-2025.
- NPM-139: Semaglutide implant for chronic weight management (preclinical stage).
- NPM-119: Exenatide implant for type 2 diabetes. FDA lifted a clinical hold in June 2024.
- OKV-119: GLP-1 implant for companion animals (cats) in collaboration with Okava Pharmaceuticals.
Strategic Update: In March 2025, the company announced a shift in strategy regarding its Neurostimulation Division (Cortigent). Efforts to pursue an IPO for Cortigent were discontinued in favor of a spin-off into an independent, publicly traded company via a Form 10 filing.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(23.5) million | $(25.7) million |
| Operating Expenses | $24.7 million | $27.0 million |
| Research & Development | $15.7 million | $17.0 million |
| General & Administrative | $8.9 million | $10.0 million |
| Cash & Cash Equivalents | $18.4 million | $20.7 million |
| Total Assets | $41.6 million | $45.8 million |
| Working Capital | $14.5 million | $17.3 million |
| Accumulated Deficit | $(121.9) million | $(98.4) million |
Note: The company has no products approved for commercial sale and has not generated revenue to date. Margins are not applicable.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $2.2 million (8.6%) compared to 2023, primarily due to staffing reductions and reduced outside services in the Neurostimulation Division, partially offset by increased clinical trial expenses in the Biopharm Division.
- Operating Expenses: Total operating expenses decreased by $2.3 million. R&D expenses declined by $1.3 million, and G&A expenses declined by $1.1 million.
- Cash Position: Cash and cash equivalents decreased by $2.3 million to $18.4 million. Net cash used in operating activities was $20.8 million.
- Financing Activities: The company raised significant capital in 2024:
- Registered direct offering (March 2024): Net proceeds of $13.7 million.
- Private sale to independent director (November 2024): Gross proceeds of $5.0 million.
- At-the-market sales (Jefferies): Net proceeds of $0.16 million.
- Regulatory Milestones: The FDA lifted the clinical hold on the NPM-119 program in June 2024. The company received regulatory approval to initiate the LIBERATE-1 trial in Australia in September 2024.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance: The company estimates that currently available cash will provide sufficient funds to meet planned obligations for at least the next twelve months. Management anticipates continuing to incur operating losses and negative operating cash flows for the foreseeable future as it advances clinical trials. Top-line data for the LIBERATE-1 trial is expected in mid-2025.
Material Risks:
- Capital Requirements: The company requires substantial additional financing to pursue business objectives. Failure to obtain capital could force delays or termination of product development.
- Clinical Development: Clinical trials involve lengthy, expensive processes with uncertain outcomes. The NPM-119 program previously faced a clinical hold (August 2023 – June 2024) due to insufficient CMC information.
- Regulatory Approval: No products are approved. Final marketing approval may be delayed, limited, or denied. The company plans to utilize the 505(b)(2) regulatory pathway for NPM-119, which carries specific risks regarding reliance on prior FDA findings.
- Spin-off Uncertainty: The proposed spin-off of Cortigent is subject to conditions and may not be completed as anticipated.
Unusual Items / Contingencies:
- Legal Proceedings: The company is involved in litigation with Pixium Vision SA regarding a terminated business combination. A Paris Commercial Court judgment ordered the company to pay approximately €1.55 million (net of prior payments). The company appealed, but the appeal was struck out in October 2024 for failure to enforce the judgment. The company must request reinstatement within two years. A litigation accrual of $1.675 million remains on the balance sheet.
- Subsequent Event: On March 26, 2025, the company entered into a private sale transaction to sell approximately 7.4 million shares to an entity affiliated with an independent director at $1.12 per share, with expected gross proceeds of $8.25 million.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $18.4 million cash balance against the projected burn rate for the LIBERATE-1 trial and ongoing operations through mid-2025.
- LIBERATE-1 Trial Status: Confirm the timeline for top-line data release (mid-2025) and monitor for any safety or enrollment issues in the Australian trial.
- Cortigent Spin-off: Monitor the progress of the Form 10 filing and the terms of the proposed spin-off, including the treatment of the intercompany loan payable.
- Legal Liability: Assess the financial impact of the Pixium Vision litigation and the likelihood of the appeal being reinstated or settled.
- Dilution Risk: Evaluate the impact of recent and planned equity financings (including the March 2025 private sale) on existing shareholder ownership.
- Regulatory Pathway: Review the company's engagement with the FDA regarding the 505(b)(2) pathway for NPM-119 and the potential need for additional cardiovascular outcomes trials.